Literature DB >> 8683120

Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.

R M Berman1, T Suzuki, H Tahara, P D Robbins, S K Narula, M T Lotze.   

Abstract

Cellular IL-10 (cIL-10), the collective term for human and murine IL-10, has both stimulatory and inhibitory effects on diverse cell types, including costimulation of T cell proliferation, chemoattraction of CD8+ T cells, and stimulation of lymphokine-activated killer cell activity. Human IL-10 (hIL-10) differs from its EBV homolog viral IL-10 (vIL-10) by only 16% at the amino acid level; however, vIL-10 shares with cIL-10 predominantly inhibitory effects, such as macrophage deactivation. We administered cIL-10 systemically to mice bearing established (day 7) sarcomas, melanomas, or colorectal carcinomas. At high doses (20 to 60 micrograms/day x 7 days), cIL-10 induced rejection of tumors, delaying tumor outgrowth or resulting in complete cure. Sublethal irradiation (500 rad) of mice prior to tumor inoculation abrogated the IL-10 effect. Cured mice were immune to subsequent rechallenge with 10-fold higher inoculation with the same, but not a different, tumor. IL-12 also has potent antitumor activity and interacts with IL-10 in both complementary and antagonistic ways; co-administration of both cytokines resulted in additive antitumor activity. To compare cIL-10 vs vIL-10 effects in vivo, we engineered CL8-1 melanoma transfectants bearing the vIL-10 or the murine IL-10 (mIL-10) gene. Local secretion of mIL-10 induced rejection of tumors, while vIL-10 resulted in accelerated outgrowth. Subsequent systemic administration of cIL-10 to mice bearing vIL-10-transduced tumors completely reversed the local suppressive effects, leading to rejection, suggesting distinct pathways for cIL-10 and vIL-10 effects. That cIL-10 can stimulate the acquisition of an effective, specific, and long-lived antitumor immune response in murine models and can reverse the local immunosuppressive effects of vIL-10 indicates a potential role for cIL-10 administration in the biologic therapy of cancer and suggests a broader interpretation of IL-10 biology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683120

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  Interleukin-10 ablation promotes tumor development, growth, and metastasis.

Authors:  Takashi Tanikawa; Cailin Moira Wilke; Ilona Kryczek; Grace Y Chen; John Kao; Gabriel Núñez; Weiping Zou
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

Review 3.  Cytokines that target immune killer cells against tumors.

Authors:  Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2020-06-10       Impact factor: 11.530

4.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Authors:  Zhaojun Sun; Julien Fourcade; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; John M Kirkwood; Hassane M Zarour
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

5.  Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.

Authors:  Shuang-Jian Qiu; Lina Lu; Chunping Qiao; LiangFu Wang; Zhong Wang; Xiao Xiao; Shiguang Qian; John J Fung; Sheng-Long Ye; C Andrew Bonham
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-08       Impact factor: 4.553

6.  Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination.

Authors:  Diana Llopiz; Fernando Aranda; Nancy Díaz-Valdés; Marta Ruiz; Stefany Infante; Virginia Belsúe; Juan José Lasarte; Pablo Sarobe
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

7.  High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2'-amino-modified RNA.

Authors:  Y Lin; D Nieuwlandt; A Magallanez; B Feistner; S D Jayasena
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

8.  Cytokine sensitivity of metastatic human melanoma cell lines-- simultaneous inhibition of proliferation and enhancement of gelatinase activity.

Authors:  A Ladányi; J O Nagy; A Jeney; J Tímár
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

9.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

10.  PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO.

Authors:  Ivan H Chan; Victoria Wu; Melissa Bilardello; Brett Jorgenson; Harminder Bal; Scott McCauley; Peter Van Vlasselaer; John B Mumm
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.